Taken together, our findings have provided new insights on the role of OSM-OSMR signaling in promoting cisplatin resistance in ovarian cancer and opportunities to reverse cisplatin-resistant mechanisms in ovarian cancer through targeting anti-OSMR antibodies. This evidence concerns the gene OSMR and ovarian carcinoma.